BMO Capital Maintains Outperform on Taysha Gene Therapies, Raises Price Target to $14
Benzinga Newsdesk 4 months ago
Analyst RatingsNewsPrice Target
BMO Capital analyst Keith Tapper maintains Taysha Gene Therapies (NASDAQ:TSHA) with a Outperform and raises the price target from $10 to $14.
BMO Capital analyst Keith Tapper maintains Taysha Gene Therapies (NASDAQ:TSHA) with a Outperform and raises the price target from $10 to $14.